Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 3/20 | 0.46 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29702562 | 1.00 | CASP3 (0.55) | CASP3MDM2KMT2ATLR2C3AR1 | |
| SCHEMBL13044089 | 1.00 | CASP3 (0.55) | CASP3MDM2KMT2ATLR2C3AR1 | |
| SCHEMBL29407920 | 1.00 | CASP3 (0.55) | CASP3MDM2KMT2ATLR2C3AR1 | |
| SCHEMBL13830553 | 1.00 | CASP3 (0.55) | CASP3MDM2KMT2ATLR2C3AR1 | |
| SCHEMBL31045201 | 1.00 | CASP3 (0.55) | CASP3MDM2KMT2ATLR2C3AR1 | |
| SCHEMBL3193169 | 1.00 | CASP3 (0.55) | CASP3MDM2KMT2ATLR2C3AR1 | |
| SCHEMBL29580018 | 1.00 | CASP3 (0.55) | CASP3MDM2KMT2ATLR2C3AR1 | |
| SCHEMBL13401540 | 1.00 | CASP3 (0.55) | CASP3MDM2KMT2ATLR2C3AR1 | |
| SCHEMBL31456589 | 0.93 | CASP3 (0.51) | CASP3MDM2KMT2ATLR2 | |
| SCHEMBL29899681 | 0.93 | CASP3 (0.53) | CASP3MDM2KMT2ATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10835616-B2 | Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of PEG | POLYTHERICS LIMITED (GB) | 2020-11-17 | — | — | US | disclosed |
| US-20170304461-A1 | Process For The Conjugation Of A Peptide Or Protein With A Reagent Comprising A Leaving Group Including A Portion Of PEG | POLYTHERICS LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| US-20170290925-A1 | Conjugates And Conjugating Reagents | POLYTHERICS LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| WO-2016148674-A1 | CONJUGATES FOR TREATING DISEASES | ENDOCYTE, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
| WO-2011001052-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304461-A1 | Process For The Conjugation Of A Peptide Or Protein With A Reagent Comprising A Leaving Group Including A Portion Of PEG | LNPEP, ANPEP, NGLY1 | CASP3 4197/4885MDM2 1134/4885KMT2A 3686/4885 |
| US-20170290925-A1 | Conjugates And Conjugating Reagents | ANPEP, NGLY1, PCTP | CASP3 4015/4885MDM2 2441/4885KMT2A 3168/4885 |
| US-10835616-B2 | Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of PEG | LNPEP, ANPEP, NGLY1 | CASP3 4197/4885MDM2 1134/4885KMT2A 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.